{"title":"非典型溶血性尿毒综合征的诊断与治疗进展。","authors":"Paula Hb Bolton-Maggs","doi":"10.3410/M2-73","DOIUrl":null,"url":null,"abstract":"<p><p>New understanding of the underlying pathology of the thrombotic microangiopathies has resulted in guidelines for the investigation and management of atypical haemolytic uraemic syndrome in children and adults and the prospect of new therapies, which are in clinical trial. Patients should be investigated for defects in complement pathways and a trial of plasma exchange is indicated.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"2 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2010-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954421/pdf/","citationCount":"1","resultStr":"{\"title\":\"Recent advances in diagnosis and treatment of atypical haemolytic uraemic syndrome.\",\"authors\":\"Paula Hb Bolton-Maggs\",\"doi\":\"10.3410/M2-73\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>New understanding of the underlying pathology of the thrombotic microangiopathies has resulted in guidelines for the investigation and management of atypical haemolytic uraemic syndrome in children and adults and the prospect of new therapies, which are in clinical trial. Patients should be investigated for defects in complement pathways and a trial of plasma exchange is indicated.</p>\",\"PeriodicalId\":88480,\"journal\":{\"name\":\"F1000 medicine reports\",\"volume\":\"2 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954421/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000 medicine reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3410/M2-73\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000 medicine reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3410/M2-73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Recent advances in diagnosis and treatment of atypical haemolytic uraemic syndrome.
New understanding of the underlying pathology of the thrombotic microangiopathies has resulted in guidelines for the investigation and management of atypical haemolytic uraemic syndrome in children and adults and the prospect of new therapies, which are in clinical trial. Patients should be investigated for defects in complement pathways and a trial of plasma exchange is indicated.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
